Abstract
We have not added the abstract for this paper yet. The publisher's page has the full record.
04-04-03: Additional results from a phase ii study to assess the clinical and immunological activity, safety, and tolerability of affitope® ad02 in patients with early Alzheimer's disease (AD)
Alzheimer's & Dementia · Vol. 11 Published January 1, 2015
More on these topics
Browse all publications →-
2026 · Nat Med
Target product profiles for treatments to delay or prevent symptomatic Alzheimer's disease
-
2025 · Neurotherapeutics
Evaluation of exploratory fluid biomarkers from a phase 1 senolytic trial in mild Alzheimer's disease
-
2025 · J Prev Alzheimers Dis
Donanemab: Appropriate use recommendations
-
2024 · Alzheimer's Association International Conference (AAIC)
Navigating the Complexities of Alzheimer's Clinical Trials: The Perils of Small Molecule Studies and the Risk of Fraudulent Practices